Previous 10 | Next 10 |
Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention...
Penny Stocks To Watch As Earnings Season Rolls On It’s earnings season but that hasn’t distracted the market from things like the coronavirus or the Fed meeting. But given this, the higher volatility market has brought more attention to penny stocks . When investors look for big...
TEL AVIV, Israel, Jan. 29, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that a successful live case featuring CGuard™ EPS ...
Penny Stocks To Watch After News If there’s one thing that can trigger a rally in penny stocks , it’s news. Whether it comes from a major industry leader or the company itself, penny stock news can become a big factor in breakouts or break downs. In fact, many times you’...
TEL AVIV, Israel, Jan. 27, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Carotid Embolic Prevention System (EPS) wi...
Are These 5 Companies On Your List Of Penny Stocks Right Now? There’s no doubt that penny stocks are best known for volatility. No matter how you look at it, the general feeling about these cheap stocks is speculative in nature. However, one thing you shouldn’t do as a trader i...
aTyr Pharma (NASDAQ: LIFE ) +63% on Kyorin Pharma deal . More news on: aTyr Pharma, Inc., Town Sports International Holdings, Inc., Pulmatrix, Inc., Stocks on the move, Read more ...
TEL AVIV, Israel, Jan. 06, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced strong preliminary unaudited revenue for the fo...
Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer Appointment adds significant medical technology commercialization experience to the InspireMD team TEL AVIV, Israel, Dec. 10, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), ...
CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations Data from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use of CGuard™ EPS in routine clinical practice is associated with no major peri...
News, Short Squeeze, Breakout and More Instantly...
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prev...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...